FDAAI& Medical Products Paper advocates for a tailoredrisk-based regulatory framework
The Food and Drug Administration's (FDA's) Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER)…
Read the original at Lexology ↗
- Topics
- HealthcareRegulation & PolicyGovernance & Risk ManagementMarkets & Investment
- Mentions
- FDA
- Tags
- AI Use Case
- Tracked via
- Google Alert “AI Risks”
Same story, other outlets
- FDAAI& Medical Products Paper advocates for a tailoredrisk-based regulatory framework jdsupra.com · Apr 04, 2024